|
I |
Systematic review |
|
II |
Proper RCT |
|
III-1 |
Pseudo RCT |
|
III-2 |
Comparative study with concurrent control -Cohort study -Case-control study |
|
III-3 |
Comparative study without concurrent control |
|
IV |
Case series |
|
V |
Case report |
|
A |
Excellent |
· Many good trials · Guides practice |
|
B |
Good |
· Couple of good trials · Guides practice in most situations |
|
C |
Satisfactory |
· Couple of ok trials · Careful with application |
|
D |
Poor |
· Low quality trials · Beware application |
|
Phase |
Numbers |
Purpose |
|
0 |
10-20 |
Kinetics |
|
1 |
20-100 |
Safety + dose finding |
|
2 |
100-300 |
Safety + efficacy |
|
3 |
1k-2k |
Safety + efficacy |
|
4 |
Many |
Safety + efficacy |
|
Type |
Explanation |
Mitigation |
|
Hawthorne effect |
Being studied = feel good |
Control group |
|
Sampling bias |
Study participants are not reflective of the population |
Appropriate inclusion and exclusion criteria |
|
Selection |
Intervention and control groups are not the same |
Randomisation |
|
Performance |
Unequal care between groups |
Identical care except for intervention vs control |
|
Attrition |
Unequal withdrawal between groups |
Impossible to overcome |
|
Reporting |
Some findings reported, others not |
|
|
Response |
Questions encourage a certain type of answer |
Control group |
|
Recall |
Patient reports symptoms differently depending upon allocation |
Patient blinding |
|
Detection |
Intervention and control group assessed differently |
Assessor blinding Pre-defined criteria |
|
Observer |
Data collector able to be subjective about the outcome |
Assessor blinding Hard outcomes |
|
Publication |
Negative results don’t get published |
Clinical trial registries |
|
Definitions |
· Narrative review: pick and choose according to your world view · Systematic review: combined systematic analysis of multiple studies · Meta-analysis: combined quantitative analysis of multiple studies |
|
Stages |
· Define inclusion and exclusion criteria · Search for trials · Assess heterogeneity · Perform meta-analysis · Assess whether result makes sense |
|
Forest plot |
= what’s the outcome? · X axis: odds ratio · Y axis: individual studies · Dot size: weight · Line width: confidence intervals · Diamond centre: point estimate · Diamond width: confidence interval |
|
Funnel plot |
= is there publication bias? · Large studies should cluster around the true effect · Publication bias is suspected if results cluster on one side of the plot |
|
Pros |
· Statistical power · Generalisability |
|
Cons |
· Whether to combine apples and oranges · How to combine apples and oranges |
|
Interpretation |
· Negative result -> probably accept · Positive result -> probably do a large RCT to confirm |
|
Indications |
· Long latency · Rare outcome · Unethical intervention · Unethical to wait |
|
Process |
e.g. case-case control study · Generate hypothesis: exposure -> outcome · Find patients with exposure · Find patients with no exposure · Match them in as many ways as possible · Calculate odds ratio |
ANZCA version:
|
Introduction |
· Appropriate question · Appropriate study design · Appropriate endpoint |
|
Research methods |
· Measurement techniques · Who, where, when, how many, how long for · Control group, randomization, blinding · Inclusion and exclusion criteria |
|
Result |
· Answers the question? · Statistically significant? · Presented clearly? · Missing data and why? |
|
Discussion & conclusion |
· Logical? · Biased? |
|
Summary |
· Quality? · Relevance? · Changes my practice? |
Simple version:
|
Intro |
Why did they bother? · Original? · Incremental? · Significant? |
|
Method |
Did they do it properly? · Right subjects? · Right intervention? · Right outcome of interest? |
|
Result |
What did they find? · What is the result? · Is it statistically significant? · Is it clinically significant? · If positive, why? (positive IRL, or confounder?) · If negative, why? (negative IRL, or underpowered?) · If fancy statistics, why? · If missing patients, why? |
|
Implication |
What does this mean? · Does this change what I think? (balance of evidence) · Does this change what I should do? (patient population) · Does this change what I could do? (feasibility) |
Feedback welcome at ketaminenightmares@gmail.com